AtriCure (NASDAQ:ATRC) Insider Salvatore Privitera Sells 3,657 Shares

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 3,657 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00. Following the transaction, the insider owned 147,264 shares in the company, valued at $8,099,520. This trade represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The stock was sold at an average price of $52.50, for a total transaction of $407,557.50.

AtriCure Price Performance

ATRC opened at $52.96 on Friday. The company has a market capitalization of $2.69 billion, a P/E ratio of 252.20 and a beta of 1.26. The company has a 50-day moving average of $41.96 and a 200-day moving average of $33.40. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $55.72.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter last year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities analysts expect that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On AtriCure

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of AtriCure during the 2nd quarter worth approximately $125,198,000. Wellington Management Group LLP boosted its position in AtriCure by 8.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after purchasing an additional 322,818 shares during the period. California State Teachers Retirement System grew its stake in AtriCure by 2,627.3% during the 2nd quarter. California State Teachers Retirement System now owns 1,634,927 shares of the medical device company’s stock worth $45,745,000 after buying an additional 1,574,980 shares during the last quarter. First Light Asset Management LLC grew its stake in AtriCure by 32.0% during the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after buying an additional 285,083 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in AtriCure by 8.2% in the first quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after buying an additional 75,862 shares during the period. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ATRC. Raymond James Financial set a $52.00 price target on AtriCure in a report on Tuesday, July 21st. BTIG Research raised their price objective on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, August 24th. UBS Group decreased their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Piper Sandler lifted their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Finally, Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.